Simplify Genomics and SimonMed Announce Collaboration to Advance Preventive Healthcare Through Integrated Genomics and Imaging 

Simplify Genomics and SimonMed Announce Collaboration to Advance Preventive Healthcare Through Integrated Genomics and Imaging 
Combining whole genome interpretation with large-scale whole-body MRI to enable a more comprehensive view of human health 

San Diego, CA — June 29, 2026 — Simplify Genomics today announced a collaboration with SimonMed aimed at advancing a more integrated approach to preventive healthcare. By combining SimonMed’s national scale in whole-body MRI with Simplify’s Whole Genome Interpretation and Reporting Platform, the collaboration seeks to provide a more complete picture of human health— helping identify risk earlier, personalize care pathways, and support more proactive health decisions. Across both imaging and genomics, there is growing evidence that early indicators associated with disease may be identified well before they surface in traditional care pathways. Together, these modalities offer complementary perspectives: genomics can provide insight into underlying disease risk, while imaging can help identify existing structural or physiological changes. 

Simplify Genomics has spent years developing and refining its clinical reporting platform as a CAP/CLIA-certified laboratory and has processed in excess of 50,000 whole genomes to date. The platform includes thousands of disease associations and a broad set of pharmacogenomic insights, designed to support clinical interpretation and integration within real-world care settings. 

Paired with SimonMed’s leadership in accessible, AI-enhanced imaging at national scale—including a network of more than 175 imaging centers across the United States —the collaboration creates an opportunity to explore patterns and connections that may not be visible through any single modality alone, supporting earlier insight and helping to inform clinical decision-making. 

SimonMed Launches Shield Program to Support Preventive Whole-Body MRI Access for Military, Veterans, and First Responders

“This collaboration reflects a shared vision for the future of healthcare—one that is more proactive, data-driven, and personalized,” said Travis Lacey, CEO of Simplify Genomics. 

“We believe the future of healthcare lies in making advanced preventive insights more accessible and actionable,” said John Simon, CEO of SimonMed. “By combining imaging and genomics, we have an opportunity to help patients and providers better understand health risk earlier and with greater clarity.” The collaboration is progressing rapidly, with additional updates expected in the near future. 

Read SimonMed Related News

About Simplify Genomics 
Simplify Genomics is a CAP/CLIA-certified clinical laboratory focused on advancing the use of whole genome sequencing in healthcare. Spun out of Human Longevity in 2022, the company has developed a comprehensive Whole Genome Interpretation and Reporting Platform that integrates thousands of disease associations and pharmacogenomic insights to support clinical interpretation in real-world care settings. Simplify Genomics has processed more than 50,000 whole genomes and is committed to expanding access to high-quality genomic insights while enabling a more proactive, personalized approach to health. 
 

About SimonMed 

Headquartered in Scottsdale, Arizona, SimonMed is one of the largest outpatient diagnostic imaging and health technology providers in the United States. SimonMed operates more than 175 centers across 10 states and is supported by a nationwide team of more than 300 subspecialty-trained, board-certified radiologists. SimonMed provides the full spectrum of diagnostic imaging services from X-ray to complex Cardiac MRI and is a recognized leader in the clinical use of artificial intelligence.  

SimonMed Longevity is a division focused on proactive health. It offers whole-body MRI and preventive, multi-modality screening designed to help patients establish a baseline of their health, track changes over time, and identify potential risk earlier—when informed action may help prevent or delay disease.